Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B.

[Guest guest]

J Med Virol. 2011 Nov;83(11):1905-8. doi: 10.1002/jmv.22192.

Lamivudine resistance mutations in European patients with hepatitis B and

patients co-infected with HIV and hepatitis B.

Taramasso L, Caligiuri P, Di Biagio A, Bruzzone B, Rosso R, Icardi G, Viscoli C.

Source

Infectious Diseases Department, San o Hospital and University of Genoa,

Genoa, Italy.

Abstract

Evaluation of resistance pattern in patients with chronic hepatitis B.

Retrospective study of hepatitis B virus (HBV) resistance mutations in patients

found viraemic after first-line treatment. HBV viral load was determined by a

real-time polymerase chain reaction and the substitutions in HBV-DNA were

studied by polymerase sequencing test. First line treatment had failed in 12 out

of 33 patients (36%) receiving anti-HBV drugs. The 12 patients with persistent

viraemia were all lamivudine (LAM) experienced and 7 had a polymerase sequencing

test available. LAM substitution mutations L180M + M204V/I were found in six

out of seven cases, with an accompanying V173L mutation in three cases. These

mutations were also related with changes in HBsAg. The use of potent drugs in

the first line anti-HBV therapy may reduce the resistance mutations in the

future.

J. Med. Virol. 83:1905-1908, 2011. © 2011 Wiley-Liss, Inc.

Copyright © 2011 Wiley-Liss, Inc.

PMID: 21915864 [PubMed - in process]

[Guest guest]

J Med Virol. 2011 Nov;83(11):1905-8. doi: 10.1002/jmv.22192.

Lamivudine resistance mutations in European patients with hepatitis B and

patients co-infected with HIV and hepatitis B.

Taramasso L, Caligiuri P, Di Biagio A, Bruzzone B, Rosso R, Icardi G, Viscoli C.

Source

Infectious Diseases Department, San o Hospital and University of Genoa,

Genoa, Italy.

Abstract

Evaluation of resistance pattern in patients with chronic hepatitis B.

Retrospective study of hepatitis B virus (HBV) resistance mutations in patients

found viraemic after first-line treatment. HBV viral load was determined by a

real-time polymerase chain reaction and the substitutions in HBV-DNA were

studied by polymerase sequencing test. First line treatment had failed in 12 out

of 33 patients (36%) receiving anti-HBV drugs. The 12 patients with persistent

viraemia were all lamivudine (LAM) experienced and 7 had a polymerase sequencing

test available. LAM substitution mutations L180M + M204V/I were found in six

out of seven cases, with an accompanying V173L mutation in three cases. These

mutations were also related with changes in HBsAg. The use of potent drugs in

the first line anti-HBV therapy may reduce the resistance mutations in the

future.

J. Med. Virol. 83:1905-1908, 2011. © 2011 Wiley-Liss, Inc.

Copyright © 2011 Wiley-Liss, Inc.

PMID: 21915864 [PubMed - in process]